CA3096821A1 - Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) - Google Patents

Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Download PDF

Info

Publication number
CA3096821A1
CA3096821A1 CA3096821A CA3096821A CA3096821A1 CA 3096821 A1 CA3096821 A1 CA 3096821A1 CA 3096821 A CA3096821 A CA 3096821A CA 3096821 A CA3096821 A CA 3096821A CA 3096821 A1 CA3096821 A1 CA 3096821A1
Authority
CA
Canada
Prior art keywords
fusion protein
npp1
seq
patient
hsnpp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096821A
Other languages
English (en)
French (fr)
Inventor
Tayeba KHAN
Andre Marozsan
Kim ASKEW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inozyme Pharma Inc
Original Assignee
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc filed Critical Inozyme Pharma Inc
Publication of CA3096821A1 publication Critical patent/CA3096821A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3096821A 2017-09-27 2018-09-26 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Pending CA3096821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563829P 2017-09-27 2017-09-27
US62/563,829 2017-09-27
PCT/US2018/052795 WO2019067502A1 (en) 2017-09-27 2018-09-26 METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
CA3096821A1 true CA3096821A1 (en) 2019-04-04

Family

ID=63858139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096821A Pending CA3096821A1 (en) 2017-09-27 2018-09-26 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)

Country Status (5)

Country Link
US (2) US12134790B2 (enExample)
EP (1) EP3687565A1 (enExample)
JP (3) JP7511469B2 (enExample)
CA (1) CA3096821A1 (enExample)
WO (1) WO2019067502A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CA3180119A1 (en) * 2020-05-27 2021-12-02 Frank RUTSCH Compositions and methods for inhibiting vascular smooth muscle cell proliferation
KR20230048480A (ko) * 2020-05-27 2023-04-11 이노자임 파마, 인코포레이티드 말초 동맥 질환을 치료하기 위한 조성물 및 방법
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
MX2024003506A (es) * 2021-09-24 2024-04-23 Inozyme Pharma Inc Formulaciones de polipéptidos enpp1 liofilizados y usos de estas.

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
JPH04292169A (ja) 1991-03-19 1992-10-16 Sekisui Chem Co Ltd ハイブリッド型人工膵臓
US5418618A (en) 1992-03-09 1995-05-23 Mita Industrial Co., Ltd. Tone processing method for forming a halftone image
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5808656A (en) 1993-09-15 1998-09-15 Oce Printing Systems Gmbh Arrangement and process for generating a matrix image on a photosensitive recording substrate
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
AU752946B2 (en) 1997-10-16 2002-10-03 Avigenics, Inc. Vectors comprising a magnum-specific promoter for avian transgenesis
PT1032662E (pt) 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
HK1044468A1 (zh) 1998-12-03 2002-10-25 海斯塔泰克有限责任公司 治療哮喘和炎症的小肽和方法
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
JP3983449B2 (ja) 1999-10-15 2007-09-26 株式会社リコー パルス幅変調回路、光書き込み装置及び画像形成装置
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE447622T1 (de) 2000-02-23 2009-11-15 Pxe Internat Inc Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen
JP2001274989A (ja) 2000-03-27 2001-10-05 Ricoh Co Ltd 画像処理装置及び画像処理方法並びにプリンタ出力装置
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20040030167A1 (en) 2000-08-08 2004-02-12 Hiroaki Takayama 3-Methyl-20-epi-vitamin d derivatives
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
WO2003025146A2 (en) 2001-09-18 2003-03-27 Avigenics, Inc. Production of a transgenic avian by cytoplasmic injection
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US9055984B2 (en) 2004-04-21 2015-06-16 DePuy Synthes Products, Inc. Sternal reconstruction system
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
EP1813671A4 (en) 2004-11-19 2008-06-11 Ono Pharmaceutical Co SOLUBLE PROTEIN AND USE THEREOF
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
CA2610159C (en) 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
EP1736553A1 (en) 2005-06-17 2006-12-27 Centre National De La Recherche Scientifique ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
US20090180989A1 (en) 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
US11039942B2 (en) 2006-06-13 2021-06-22 Sino Medical Sciences Technology Inc. Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
WO2008065225A2 (es) 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
DK2662448T3 (en) 2007-05-11 2017-03-20 Alexion Pharma Inc Bone-targeted alkaline phosphatase, kits and methods for its use
EP2178556B1 (en) 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP4888439B2 (ja) 2008-05-30 2012-02-29 ブラザー工業株式会社 画像読取装置および原稿サイズ決定プログラム
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
EP2683742B1 (en) 2011-03-11 2018-12-19 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
WO2012130567A1 (en) 2011-03-29 2012-10-04 Beta-Cell Nv Method for encapsulated therapeutic products and uses thereof
WO2013074615A1 (en) 2011-11-14 2013-05-23 Yale University Compositions and methods for modulating coagulation
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PL2956163T3 (pl) 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
CA2924259C (en) 2013-09-19 2021-12-21 Universitatsspital Basel Artificial vascular graft
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
HK1245662A1 (zh) 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
TN2018000163A1 (en) 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
JP2021523139A (ja) 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法

Also Published As

Publication number Publication date
JP7511469B2 (ja) 2024-07-05
US12134790B2 (en) 2024-11-05
WO2019067502A1 (en) 2019-04-04
US20200263153A1 (en) 2020-08-20
JP2020535161A (ja) 2020-12-03
US20250019677A1 (en) 2025-01-16
EP3687565A1 (en) 2020-08-05
JP7598960B2 (ja) 2024-12-12
JP2023033610A (ja) 2023-03-10
JP2025023189A (ja) 2025-02-14

Similar Documents

Publication Publication Date Title
US20250019677A1 (en) Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
ES2356286T3 (es) Composiciones para inhibir la proteincinasa c-alfa para el tratamiento de diabetes mellitus.
USRE49529E1 (en) Methods of treating tissue calcification
WO2009156481A1 (en) Pegylated bnp
CN110087666B (zh) 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
CN115867306A (zh) ActRII蛋白以及在治疗毛细血管后肺高压中的用途
US20220354933A1 (en) Methods of treating myointimal proliferation
CN109069595A (zh) 标靶医疗性溶酶体酵素融合蛋白质、其相关调配物与用途
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
AU2017213440A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
JP6516855B2 (ja) Ｃ１エステラーゼ阻害剤の医薬製剤
CN101394861A (zh) 纽兰格林持续给药能改善心脏功能
KR20260006552A (ko) Igf-1 키메라 단백질을 이용한 치료 방법
CN112585159A (zh) 神经调节蛋白多肽片段及其用途
TWI737972B (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
JP2022516199A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
Liu et al. Cardiovascular pharmacology: an update
HK40116513A (en) Methods of treating tissue calcification
US20230173029A1 (en) Treatment of cardiac remodelling
EA049479B1 (ru) БЕЛКИ ActRII И ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ПОСТКАПИЛЛЯРНОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ
HK40070846B (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
HK40070846A (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
HK1196944B (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240918

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240918

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240918

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260102

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729